We help research teams evaluate the strength, relevance, and limitations of existing biomedical evidence before committing to the next stage of therapeutic development.
The research question
Programs accumulate findings from different models, assays, and publications that rarely agree completely. This capability assembles that evidence into one structured view, so the decision to proceed, redesign, or stop rests on what the evidence actually supports.
Approach and methods
Four areas of assessment
Biological rationale and target evidence
- Strength and consistency of the mechanistic rationale
- Target expression and relevance to the disease context
- Quality of the models behind key findings
Translational evidence mapping
- Findings organized against the development question
- Agreement and conflict between studies made explicit
- Assumptions carried between evidence layers identified
Biomarker and study readiness
- Whether proposed biomarkers measure the intended process
- Assay readiness for the planned study
- Endpoints matched to the decision at stake
Research gaps and development options
- Gaps ranked by how much they affect the decision
- Options for closing each gap, with expected value
- Findings that would change the recommendation
Deliverables
What an engagement produces
- Evidence map — findings organized against the research question, with sources.
- Structured scientific review — interpretation, assumptions, and limitations, reviewed.
- Research gap assessment — what is missing, and how much it matters.
- Next-study recommendations — prioritized follow-up work tied to the decision.
Scope and limitations
Scope: Evidence assessment works from published literature, study documentation, and data the client is authorized to share. It does not generate new experimental data. These reports are scientific assessments — they are not described as FDA-approved or regulatory-grade, and they do not substitute for regulatory advice.
Relevant applications
Precision oncology program decisions, radiopharmaceutical candidate evaluation, and biomarker strategy across targeted therapeutic programs.
Have an evidence question before your next study?
Tell us the decision at stake and the evidence involved.